Demographic characteristics study population
| Variables | Total cohort (n=118) | Confirmed stroke* (n=48) |
| Age (mean±SD) | 64.9±15.7 | 64.4±15.4 |
| Male gender | 57.6% (68) | 60.4% (29) |
| Stroke* | 40.7% (48) | 100% (48) |
| COVID related apical findings on CTA† | 28.0% (33) | 37.5% (18) |
| Ground-glass opacity | 28.0% (33) | 37.5% (18) |
| Consolidation | 5.1% (6) | 6.3% (3) |
| COVID (+) on nasal swab RT-PCR | 26.3% (31) | 37.5% (18) |
| Diabetes type II | 40.7% (48) | 37.5% (18) |
| Hypertension | 73.7% (87) | 77.1% (37) |
| Coronary artery disease | 28.8% (34) | 27.1% (13) |
| Congestive heart disease | 10.2% (12) | 10.4% (5) |
| Dyslipidemia | 41.5% (49) | 39.6% (19) |
| Atrial fibrillation | 23.7% (28) | 29.2% (14) |
| Prior stroke | 28.8% (34) | 29.2% (14) |
| BMI (mean±SD) | 28.1±6.2 | 28.4±6.1 |
| Smoking status | 33.1% (39) | 33.3% (16) |
| Current | 12.7% (15) | 14.6% (7) |
| Former | 20.3% (24) | 18.8% (9) |
| NIH Stroke Scale (mean±SD) | 9.2±8.7 | 12.0±8.0 |
| Common presenting neurological symptoms | ||
| Altered mental status | 34.7% (41) | 25.0% (12) |
| Headache | 19.5% (23) | 12.5% (6) |
| Dysarthria | 38.1% (45) | 52.1% (25) |
| Syncope/unresponsiveness | 15.3% (18) | 14.6% (7) |
| Facial droop | 28.8% (34) | 50.0% (24) |
| Numbness | 29.7% (35) | 37.5% (18) |
*Stroke that is confirmed on imaging.
†Apical findings on CTA indicative of COVID-19 infection include typical and indeterminate findings. Note that indeterminate findings are considered secondary to COVID-19 infection during pandemic.